Table 2.

Comparison of Clinical and Biochemical Characteristics in Patients With LC With or Without Carnitine Supplementation at the Second CT Imaging Point

Variables	Overall (n = 70)	L‐Carnitine Oral Administration Group (n = 35)	L‐Carnitine Nonoral Administration Group (n = 35)	P Value
Psoas muscle mass (at 2nd CT)	M 3.25 (1.10‐5.77) F 1.94 (0.74‐3.52)	M 3.47 (1.10‐5.77) F 1.97 (0.74‐3.52	M 3.22 (1.15‐4.84) F 1.83 (0.88‐3.31)	M 0.49 F 0.96
White blood cell count,/μL	4,100 (1,200‐12,200)	3,800 (1,900‐6,300)	4,400 (1,200‐12,200)	<0.01
NLR	2.85 (0.59‐9.86)	3.10 (0.88‐9.86)	2.70 (0.59‐8.70)	0.60
Hemoglobin, mg/dL	11.8 (6.7‐18.2)	11.2 (6.7‐17.3)	12.8 (7.3‐18.2)	0.04
Platelet counts, ×104/mm3	9.3 (2.1‐31.2)	7.7 (3.2‐31.2)	11.1 (2.1‐25)	<0.01
Prothrombin time, %	70.8 (29.5‐106.2)	63 (30‐97.6)	74.2 (29.5‐106.2)	0.03
Serum albumin, g/dL	3.7 (1.8‐4.7)	3.2 (1.8‐4.5)	3.8 (2.2‐4.7)	<0.01
Total bilirubin, mg/dL	1.1 (0.3‐4.6)	1.4 (0.3‐3.5)	1.1 (0.4‐4.6)	0.17
Aspartate aminotransferase, IU/L	34 (12‐157)	37 (23‐140)	31 (12‐157)	0.13
Alanine aminotransferase, IU/L	25 (7‐89)	27 (11‐65)	22 (7‐89)	0.11
γ‐glutamyltransferase, IU/L	44 (10‐607)	32 (10‐588)	80 (12‐607)	<0.01
Ammonia, mg/dL	53 (9‐349)	67 (9‐349)	53 (15‐190)	0.55
Cholinesterase, IU/L	185 (26‐394)	153 (26‐281)	204 (99‐394)	<0.01
eGFR, mL/minute/1.73 m2	72.3 (27.4‐176.7)	65.6 (37.4‐176.7)	78.3 (27.4‐140.9)	0.37
C reactive protein, mg/dL	0.13 (0.02‐4.11)	0.22 (0.02‐9.58)	0.115 (0.02‐2.26)	0.51
HbA1c, %	5.8 (3.4‐9.2)	5.8 (3.4‐9.2)	5.85 (4.6‐9.0)	0.39
Alpha‐fetoprotein, ng/mL	4.7 (1.0‐413503)	7.8 (1.0‐38,967.0)	4.0 (1.2‐413,503)	0.30
FIB4‐index	5.65 (0.73‐27.17)	6.69 (0.73‐18.77)	3.91 (1.24‐27.17)	0.01

Data are presented as number of patients or median (range) values.

Abbreviations: eGFR, estimated glomerular filtration ratio; FIB4, fibrosis‐4; HbA1c, hemoglobin A1c; NLR, neutrophil–lymphocyte ratio.